I think the answer to this is that, from the start, the patient populations are very small in pediatrics. Also, these are disease states that are almost regularly rare diseases. The formulation problems happen with drugs that have been on the market for many years, have become generic and are now accessible at a very low price for Canadians. Formulating a pediatric drug requires some additional R and D investment in formulation at a time in the life cycle of the product where this product is no longer profitable, so it's this joint—
On February 7th, 2019. See this statement in context.